MAPT and neurodegenerative disease: Antibody pharmacodynamics was confirmed in the SAA with the use of a specific mAb ACI-5891.9 that does not cross-react with other prion-like proteins28 such as β-amyloid, α-synuclein or tau implicated in neurodegeneration.42 As the co-pathology of these proteins is commonly found in neurodegenerative diseases, their presence theoretically could influence the seeding observed in the SAA.